RESUMEN
OBJECTIVES: To evaluate the efficacy of human-simulated regimens (HSRs) of ceftazidime, ceftazidime/avibactam, imipenem, imipenem/relebactam, meropenem and meropenem/vaborbactam in a murine thigh infection model against serine carbapenemase-producing Pseudomonas aeruginosa. METHODS: Nine P. aeruginosa clinical isolates harbouring GES-5 (n = 1), GES-20 (n = 1), GES-5/20 (n = 1), GES-19, GES-20 (n = 3) and KPC (n = 3) were evaluated. Six mice were administered HSRs of ceftazidime 2â g q8h (2â h infusion), ceftazidime/avibactam 2.5â g q8h (2â h infusion), meropenem 2â g q8h (3â h infusion), imipenem 0.5â g q6h (0.5â h infusion), imipenem/relebactam 1.25â g q6h (0.5â h infusion) and meropenem/vaborbactam 4â g q8h (3â h infusion). Change in bacterial burden relative to baseline and the percent of isolates meeting the 1â log10 kill endpoint were assessed. RESULTS: The addition of avibactam to ceftazidime increased the percentage of isolates meeting 1â log10 kill from 33% to 100% of GES- or KPC-harbouring isolates. Imipenem/relebactam HSR produced ≥1â log10 of kill against 83% and 100% of GES- and KPC-harbouring isolates, respectively, while imipenem alone failed to reach 1â log10 kill for any isolates. Vaborbactam resulted in variable restoration of meropenem activity as 1â log10 kill was achieved in only 33% and 66% of GES- and KPC-harbouring isolates, respectively, compared with no isolates for meropenem alone. CONCLUSIONS: Ceftazidime/avibactam and imipenem/relebactam were active against 100% and 89% of KPC- or GES-harbouring isolates tested in vivo. The activity of meropenem/vaborbactam was variable, suggesting this may be an inferior treatment option in this setting. Further studies to evaluate clinical outcomes in GES- and KPC-producing P. aeruginosa are warranted given their increasing prevalence worldwide.
Asunto(s)
Compuestos de Azabiciclo , Proteínas Bacterianas , Ácidos Borónicos , Pseudomonas aeruginosa , Inhibidores de beta-Lactamasas , beta-Lactamasas , Humanos , Animales , Ratones , Inhibidores de beta-Lactamasas/farmacología , Inhibidores de beta-Lactamasas/uso terapéutico , Meropenem/farmacología , Ceftazidima/farmacología , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Imipenem/farmacología , SerinaRESUMEN
PURPOSE: Sulbactam/durlobactam is a combination antibiotic designed to target Acinetobacter baumannii, including carbapenem-resistant and multidrug-resistant strains. The objective of this study was to determine the physical compatibility of sulbactam/durlobactam solution during simulated Y-site administration with 95 intravenous (IV) drugs. METHODS: Vials of sulbactam/durlobactam solution were diluted in 0.9% sodium chloride injection to a volume of 100 mL (the final concentration of both drugs was 15 mg/mL). All other IV drugs were reconstituted according to the manufacturer's recommendations and diluted with 0.9% sodium chloride injection to the upper range of concentrations used clinically or tested undiluted as intended for administration. Y-site conditions were simulated by mixing 5 mL of sulbactam/durlobactam with 5 mL of the tested drug solutions in a 1:1 ratio. Solutions were inspected for physical characteristics (clarity, color, and Tyndall effect), turbidity, and pH changes before admixture, immediately post admixture, and over 4 hours. Incompatibility was defined as any observed precipitation, significant color change, positive Tyndall test, or turbidity change of ≥0.5 nephelometric turbidity unit during the observation period. RESULTS: Sulbactam/durlobactam was physically compatible with 38 out of 42 antimicrobials tested (90.5%) and compatible overall with 86 of 95 drugs tested (90.5%). Incompatibility was observed with albumin, amiodarone hydrochloride, ceftaroline fosamil, ciprofloxacin, daptomycin, levofloxacin, phenytoin sodium, vecuronium, and propofol. CONCLUSION: The Y-site compatibility of sulbactam/durlobactam with 95 IV drugs was described. These compatibility data will assist pharmacists and nurses to safely coordinate administration of IV medications with sulbactam/durlobactam.
Asunto(s)
Cloruro de Sodio , Sulbactam , Humanos , Infusiones Intravenosas , Antibacterianos , Incompatibilidad de MedicamentosRESUMEN
Pseudomonas aeruginosa is a common multidrug-resistant pathogen in patients with cystic fibrosis (CF). The in vitro activity of imipenem/relebactam and imipenem was compared with other antipseudomonal antibiotics against 105 isolates from patients with CF from three US hospitals. Imipenem/relebactam, imipenem, meropenem, ceftazidime/avibactam, and ceftolozane/tazobactam susceptibilities were 77%, 55%, 58%, 90%, and 92%, respectively. Relebactam potentiates imipenem against CF P. aeruginosa by fourfold leading imipenem/relebactam to retain susceptibility against most isolates in this cohort.
Asunto(s)
Fibrosis Quística , Infecciones por Pseudomonas , Humanos , Pseudomonas aeruginosa , Antibacterianos/farmacología , Compuestos de Azabiciclo/farmacología , Imipenem/farmacología , Infecciones por Pseudomonas/tratamiento farmacológico , Ceftazidima/farmacología , Pruebas de Sensibilidad Microbiana , Combinación de MedicamentosRESUMEN
Cutaneous squamous cell carcinoma (cSCC) is the second-most common type of non-melanoma skin cancer and is linked to long-term exposure to ultraviolet (UV) radiation from the sun. Rocuronium bromide (RocBr) is an FDA-approved drug that targets p53-related protein kinase (PRPK) that inhibits the development of UV-induced cSCC. This study aimed to investigate the physicochemical properties and in vitro behavior of RocBr. Techniques such as thermal analysis, electron microscopy, spectroscopy and in vitro assays were used to characterize RocBr. A topical oil/water emulsion lotion formulation of RocBr was successfully developed and evaluated. The in vitro permeation behavior of RocBr from its lotion formulation was quantified with Strat-M® synthetic biomimetic membrane and EpiDerm™ 3D human skin tissue. Significant membrane retention of RocBr drug was evident and more retention was obtained with the lotion formulation compared with the solution. This is the first systematic and comprehensive study to report these findings.
Asunto(s)
Carcinoma de Células Escamosas , Neoplasias Cutáneas , Humanos , Rocuronio/farmacología , Carcinoma de Células Escamosas/patología , Neoplasias Cutáneas/patología , Piel/metabolismo , Preparaciones Farmacéuticas/metabolismo , Técnicas de Cultivo de CélulaRESUMEN
Nonmelanoma skin cancers (NMSCs) are the most common malignancies worldwide and affect more than 5 million people in the United States every year. NMSC is directly linked to the excessive exposure of the skin to solar ultraviolet (UV) rays. The toll-like receptor 4 (TLR4) antagonist, resatorvid (TAK-242), is a novel prototype chemo preventive agent that suppresses the production of inflammation mediators induced by UV exposure. This study aimed to design and develop TAK-242 into topical formulations using FDA-approved excipients, including DermaBaseTM, PENcreamTM, polyethylene glycol (PEG)-400, propylene glycol (PG), carbomer gel, hyaluronic acid (HA) gel, and Pluronic® F-127 poloxamer triblock copolymer gel for the prevention of skin cancer. The physicochemical properties of raw TAK-242, which influence the compatibility and solubility in the selected base materials, were confirmed using X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), hot-stage microscopy (HSM), Raman spectroscopy, and attenuated total reflectance Fourier-transform infrared (ATR-FTIR) spectroscopic analysis. The permeation behavior of TAK-242 from the prepared formulations was determined using Strat-M® transdermal diffusion membranes, and 3D cultured primary human-derived epidermal keratinocytes (EpiDermTM). Despite TAK-242's high molecular weight and hydrophobicity, it can permeate through reconstructed human epidermis from all formulations. The findings, reported for the first time in this study, emphasize the capabilities of the topical application of TAK-242 via these multiple innovative topical drug delivery formulation platforms.
RESUMEN
Wildlife data often show spatial organization, demonstrating positive correlations either as a result of processes occurring over the landscape or due to the influence of spatially structured environmental variables. It is, thus, essential to consider non-random spatial structure when evaluating the underlying causes of biological variation. In this study, we analyzed the population structure of Chilina dombeyana shell morphology of 14 populations that are close geographically and belong to the same hydrographic basin. We utilized a variation partitioning approach to evaluate the importance of spatial processes, such as migration, acting over the landscape, and environmental characteristics, including habitat and hydrologic characteristics, and the occurrence of aquatic predators in promoting between population variation. Our results demonstrate spatially structured variation in C. dombeyana shell morphology, with populations living near each other having more similar shell sizes than populations living farther apart. The shell size variation partition indicated that both spatially structured environmental factors and genetic relationships resulting from migration or shared common ancestry may explain this pattern. Shell shape variation, in contrast, was found to be essentially under the influence of non-spatially structured environmental factors, with habitat and water characteristics accounting for about half of the total variation among populations. The large proportion of the variation in shell size that is spatially structured demonstrates that spatial structure on morphological traits might be strong and highlights the need to consider such phenomenon in intraspecific studies of phenotypic evolution.